Prosecution Insights
Last updated: November 04, 2026
Application No. 17/742,855

ANTIMICROBIAL PUNCTURE SITE PATCH WITH POST INJECTION SAFETY SEALING

Final Rejection §103
Filed
May 12, 2022
Priority
May 13, 2021 — provisional 63/188,166
Examiner
DIPERT, FORREST BLAKE
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Injection Safety Industries LLC
OA Round
4 (Final)
50%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
27 granted / 54 resolved
-20.0% vs TC avg
Strong +64% interview lift
Without
With
+64.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
39 currently pending
Career history
97
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
51.3%
+11.3% vs TC avg
§102
25.5%
-14.5% vs TC avg
§112
21.3%
-18.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 54 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement(s) have been considered by the examiner. Response to Amendment This office action is responsive to the amendment filed on 9/25/2026. As directed by the amendment: claim(s) 1, 7,14, and 20 have been amended. Thus, claims 1-4, 6-14, and 16-20 are presently pending in this application. Response to Arguments Applicant's arguments filed 9/25/2026 have been fully considered but they are not fully persuasive. Applicant’s arguments with respect to the independent claim(s) 1, 14, and 20 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 103 Claims 1, 4-6, and 9-11 are rejected under 35 U.S.C. 103 as being unpatentable over WO 9504511 A1, henceforth written as Smith. Regarding Claim 1, Smith discloses: A puncture site patch, comprising: (patch 1 of embodiment of fig 3-4; fig 1-4) an -- membrane, wherein the -- membrane further including an exterior face and an interior face; (target zone 7 on membrane comprising top layer 12; fig 3-4) a spacer including an outer face and an inner face, wherein the outer face of the spacer is coupled to the interior face of the elastomeric, self-sealing membrane; (base layer 11; fig 4) wherein the spacer further includes an aperture, ( aperture (not enumerated/illustrated) formed by pentrattion of patch 1's target zone 7 with a cannula/needle; fig 3) the aperture forming a cavity defined by the interior face of the -- membrane, spacer, and skin when applied to a user; (fig 4 best illustrating a side view of a cavity spanning from top layer 12 through an needle penetration aperture axis and toward a skin surface) an adhesive film configured to adhere to skin, the adhesive film on the inner face of the spacer; (adhesive 4; fig 1+4) at least one elongated tab moveable between a first position and a second position ( elongated tab comprises cover flap 5 and backing flap 14; fig 3a illustrating a first position and fig 3d illustrating a second position) wherein the at least one elongated tab includes: a length greater than a length from a point on a perimeter defining the aperture farthest away in an extending direction from the elongated tab to a base end of the elongated tab, and a width greater than a width of the aperture; (fig 1-3) wherein in the first position the at least one elongated tab extends outward from a periphery of the spacer; (fig3a) and wherein in the second position at least one elongated tab is folded over the aperture to completely seal the cavity closed by the at least one elongated tab, (fig 3d and page 10 line 4-6, all contaminated are -therein including the claimed aperture/cavity- are securely protected and consequently completely sealed by the flap 5 and flap 14) when in the second position, the at least one elongated tab adheres to the spacer via the adhesive film to complete the seal of the cavity (fig 3d and page 10 line 4-6, all contaminated are -therein including the claimed aperture/cavity- are securely protected and consequently completely sealed by the flap 5 and flap 14) Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: an elastomeric, self-sealing membrane However Smith teaches in an alternative embodiment: an elastomeric, self-sealing membrane (page 12 line 8-15; patch 1, including zone 7, is formed from a elastomeric resealing material) Examiner notes in page 17 line 1-14 details that its embodiments may be advantageously combined Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the resealing elastomeric material taught by Smith’ alternative embodiment to Smith’s primary embodiment in order to advantageously arrive at an invention which is enabled to receive multiple injections over a period of time, see page 12 line 8-15 of Smith. The modified invention of Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: wherein the adhesive film extends onto at least a portion of the at least one elongated tab such that, However Smith teaches in page 9 line 1-3 that its cover flap 5 is an element of patch 1. Further Smith teaches in page 10 line 21-22 adhesive may be provide on a bottom side of patch 1 for adhering the dressing to skin. Specifically Smith’s page 10 line 24-34, that adhesive may be provided to a side of patch aligned with cover 5 for the securement of cover 5 to areas of skin. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the adhesive surface 4 on the underside of patch 1 of Smith such that the adhesive surface 4 extends across the underside of the cover 5 of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to implement Smith’s teachings that adhesive may be provided on a skin surface side of a patch into the modified invention of Smith, such that Smith’s adhesive film extends onto a skin surface side of Smith’s elongated tab, in order to advantageously arrive at an invention which improves temporary securement of the invention to a user’s skin, see page 10 line 24-34 of Smith. Regarding claim 4, Smith discloses: The puncture site patch of claim 1 further comprising an axis running through a center of the aperture defining a first side of the spacer and a second side of the spacer, and wherein in the second position the puncture site patch is folded along the axis such that the first side of the spacer and second side of the spacer substantially overlap each other and the at least one elongated tab is folded over the substantially overlapping first and second sides of the spacer to seal the first and second sides of the spacer closed. (such claim language of “folded along” implies a functional language and the prior art must at least be capable of performing the recited function of the patch folding/bending along the axis; accordingly in light of page 9 line 1-2 detailing that the patch 1 is formed of a thin foldable materials (e.g. silicone) and fig 3 illustrating the foldability of a such a material, accordingly the spacer of the invention would be functionally capable of the claimed bending/folding to overlap the claimed first and second sides of the spacer to seal the first and second sides of the spacer closed.) Regarding claim 5, Smith discloses: The puncture site patch of claim 1, wherein in the second position the at least one elongated tab is folded over the aperture to seal the cavity closed. (fig 3d) Regarding claim 6, Smith discloses: The puncture site patch of claim 1 further comprising a release paper in contact with and completely covering the adhesive film, wherein the release paper is configured to be removed prior to application to skin. (protective cover 30; fig 1) Regarding Claim 9, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above, including the following limitations of the present claim: The puncture site patch of claim 1, wherein [the invention] further includes an antimicrobial agent. ( page 3 line 20-28; medicated substance impregnated in absorbent material 13 includes antimicrobial substances) However, Smith is silent regarding: wherein the elastomeric, self-sealing membrane further includes an antimicrobial agent. However, Smith teaches that the patch itself may be impregnated/applied with a medicated substance page 9 line 28-30 and page 15 line 26-29. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the medicated substance in the absorbent material of patch 1 of Smith such that there is a medicated substance in another part of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to duplicate the antimicrobial medicated substance of Smith such that it is incorporated in another portion of Smith, and consequently disposed in the claimed element, in order to advantageously arrive at an invention with improved capabilities to ward off microbial contamination. Regarding claim 10, Smith discloses: The puncture site patch of claim 9, wherein the antimicrobial agent is incorporated into the elastomeric, self-sealing membrane during extrusion. (see mpep 2113; page 9 line 29-30; medicated/antimicrobial substance may be impregnated into the dressing, therein having the same structural characteristics of the apparatus – and being substantially identical to – where the antimicrobial agent is incorporated via extrusion) Regarding claim 11, Smith discloses: The puncture site patch of claim 9, wherein the antimicrobial agent is a coating applied to the elastomeric, self-sealing membrane. (see mpep 2113; page 9 line 29-30; medicated/antimicrobial substance may be applied at the time of use, therein having the same structural characteristics of the apparatus – and being substantially identical to – where the antimicrobial agent is incorporated via coating) Claim 8, 14, 17-20 are rejected under 35 U.S.C. 103 as being unpatentable over Smith, as applied to claim 1 above, in view of US 7129389 B1, henceforth written as Watson. Regarding Claim 8, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above. However Smith is silent regarding: wherein the elastomeric, self-sealing membrane is substantially transparent. However, Watson teaches a dressing patch: wherein the elastomeric, self-sealing membrane is substantially transparent. (col 3 line 21-24; membrane 12 is transparent) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the transparent membrane teachings of Watson to the membrane disclosed by Smith in order to arrive at an invention which advantageously promotes needle-skin penetration by enabling an operator visualize the skin target throughout the insertion process. Regarding Claim 14, Smith discloses: A puncture site patch, comprising: (patch 1 of embodiment of fig 3-4; fig 1-4) a -- membrane, wherein the -- membrane further including an exterior face and an interior face; (target zone 7 on membrane comprising top layer 12; fig 3-4) a spacer including an outer face and an inner face; wherein the outer face of the spacer is coupled to the interior face of the -- membrane; (base layer 11; fig 4) wherein the spacer further includes an aperture, ( aperture (not enumerated/illustrated) formed by pentrattion of patch 1's target zone 7 with a cannula/needle; fig 3) the aperture forming a cavity defined by the interior face of the -- membrane, the spacer, and skin when applied to a user; (fig 4 best illustrating a side view of a cavity spanning from top layer 12 through an needle penetration aperture axis and toward a skin surface) an adhesive film configured to adhere to skin, the adhesive film on the inner face of the spacer; (adhesive 4; fig 1+4) an axis running through a center of the aperture defining a first side of the spacer and a second side of the spacer an elongated tab configured moveable between a first position and a second position (fig 1-4) wherein the elongated tab includes a length greater than a length from a point on a perimeter defining the aperture farthest away in an extending direction from the elongated tab to a base end of the elongated tab, and a width greater than a width of the aperture; (fig 1+3) wherein in the first position the elongated tab extends outward from a periphery of the spacer; (fig 3a) and wherein in the second position the puncture site patch is folded over the axis and over the aperture to completely seal the cavity with the elongated tab: - in the second position, the at least one elongated tab adheres to the spacer via the adhesive film to complete the seal of the cavity (fig 3d) Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: an elastomeric, self-sealing membrane However Smith teaches in an alternative embodiment: an elastomeric, self-sealing membrane (page 12 line 8-15; patch 1, including zone 7, is formed from a elastomeric resealing material) Examiner notes in page 17 line 1-14 details that its embodiments may be advantageously combined Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the resealing elastomeric material taught by Smith’ alternative embodiment to Smith’s primary embodiment in order to advantageously arrive at an invention which is enabled to receive multiple injections over a period of time, see page 12 line 8-15 of Smith. The modified invention of Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: wherein the adhesive film extends onto at least a portion of the at least one elongated tab such that, However Smith teaches in page 9 line 1-3 that its cover flap 5 is an element of patch 1. Further Smith teaches in page 10 line 21-22 adhesive may be provide on a bottom side of patch 1 for adhering the dressing to skin. Specifically Smith’s page 10 line 24-34, that adhesive may be provided to a side of patch aligned with cover 5 for the securement of cover 5 to areas of skin. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the adhesive surface 4 on the underside of patch 1 of Smith such that the adhesive surface 4 extends across the underside of the cover 5 of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to implement Smith’s teachings that adhesive may be provided on a skin surface side of a patch into the modified invention of Smith, such that Smith’s adhesive film extends onto a skin surface side of Smith’s elongated tab, in order to advantageously arrive at an invention which improves temporary securement of the invention to a user’s skin, see page 10 line 24-34 of Smith. Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: wherein the elastomeric, self-sealing membrane is substantially transparent. However, Watson teaches a dressing patch: wherein the elastomeric, self-sealing membrane is substantially transparent. (col 3 line 21-24; membrane 12 is transparent) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the transparent membrane teachings of Watson to the membrane disclosed by Smith in order to arrive at an invention which advantageously promotes needle-skin penetration by enabling an operator visualize the skin target throughout the insertion process. Regarding Claim 17, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above, including the following limitations of the present claim: The puncture site patch of claim 1, wherein [the invention] further includes an antimicrobial agent. ( page 3 line 20-28; medicated substance impregnated in absorbent material 13 includes antimicrobial substances) However, Smith is silent regarding: wherein the substantially transparent elastomeric, self-sealing membrane further includes an antimicrobial agent. However, Smith teaches that the patch itself may be impregnated/applied with a medicated substance page 9 line 28-30 and page 15 line 26-29. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the medicated substance in the absorbent material of patch 1 of Smith such that there is a medicated substance in another part of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to duplicate the antimicrobial medicated substance of Smith such that it is incorporated in another portion of Smith, and consequently disposed in the claimed element, in order to advantageously arrive at an invention with improved capabilities to ward off microbial contamination. Regarding claim 18, Smith in view of Watson discloses: The puncture site patch of claim 17, wherein the antimicrobial agent is incorporated into the elastomeric, self-sealing membrane during extrusion. Smith: (see mpep 2113; page 9 line 29-30; medicated/antimicrobial substance may be impregnated into the dressing, therein having the same structural characteristics of the apparatus – and being substantially identical to – where the antimicrobial agent is incorporated via extrusion) Regarding claim 19, Smith in view of Watson discloses: The puncture site patch of claim 17, wherein the antimicrobial agent is a coating applied to the elastomeric, self-sealing membrane. Smith: (see mpep 2113; page 9 line 29-30; medicated/antimicrobial substance may be applied at the time of use, therein having the same structural characteristics of the apparatus – and being substantially identical to – where the antimicrobial agent is incorporated via coating) Regarding Claim 20, Smith discloses: A puncture site patch, comprising: (patch 1 of embodiment of fig 3-4; fig 1-4) a -- membrane, wherein the -- membrane further including an exterior face an interior face --; (target zone 7 on membrane comprising top layer 12; fig 3-4) a spacer including an outer face and an inner face; wherein the outer face of the spacer is coupled to the interior face of the -- membrane; (base layer 11; fig 4) wherein the spacer further includes an aperture, ( aperture (not enumerated/illustrated) formed by pentrattion of patch 1's target zone 7 with a cannula/needle; fig 3) the aperture forming a cavity defined by the interior face of the -- membrane, the spacer, and skin when applied to a user; (fig 4 best illustrating a side view of a cavity spanning from top layer 12 through an needle penetration aperture axis and toward a skin surface) an adhesive film configured to adhere to skin, the adhesive film on the inner face of the spacer; (adhesive 4; fig 1+4) an axis running through a center of the aperture defining a first side of the spacer and a second side of the spacer an elongated tab configured moveable between a first position and a second position (fig 1-4) wherein the elongated tab includes a length greater than a length from a point on a perimeter defining the aperture farthest away in an extending direction from the elongated tab to a base end of the elongated tab, and a width greater than a width of the aperture; (fig 1+3) wherein in the first position the elongated tab extends outward from a periphery of the spacer; (fig 3a) and wherein in the second position the puncture site patch is folded over the axis and over the aperture to completely seal the cavity with the elongated tab: - in the second position, the at least one elongated tab adheres to the spacer via the adhesive film to complete the seal of the cavity (fig 3d) Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: an elastomeric, self-sealing membrane However Smith teaches in an alternative embodiment: an elastomeric, self-sealing membrane (page 12 line 8-15; patch 1, including zone 7, is formed from a elastomeric resealing material) Examiner notes in page 17 line 1-14 details that its embodiments may be advantageously combined Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the resealing elastomeric material taught by Smith’ alternative embodiment to Smith’s primary embodiment in order to advantageously arrive at an invention which is enabled to receive multiple injections over a period of time, see page 12 line 8-15 of Smith. The modified invention of Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: wherein the adhesive film extends onto at least a portion of the at least one elongated tab such that, However Smith teaches in page 9 line 1-3 that its cover flap 5 is an element of patch 1. Further Smith teaches in page 10 line 21-22 adhesive may be provide on a bottom side of patch 1 for adhering the dressing to skin. Specifically Smith’s page 10 line 24-34, that adhesive may be provided to a side of patch aligned with cover 5 for the securement of cover 5 to areas of skin. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the adhesive surface 4 on the underside of patch 1 of Smith such that the adhesive surface 4 extends across the underside of the cover 5 of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to implement Smith’s teachings that adhesive may be provided on a skin surface side of a patch into the modified invention of Smith, such that Smith’s adhesive film extends onto a skin surface side of Smith’s elongated tab, in order to advantageously arrive at an invention which improves temporary securement of the invention to a user’s skin, see page 10 line 24-34 of Smith. Smith discloses the elements of the present claim, as described above. Yet, its present embodiment is silent on: wherein the elastomeric, self-sealing membrane is substantially transparent. However, Watson teaches a dressing patch: wherein the elastomeric, self-sealing membrane is substantially transparent. (col 3 line 21-24; membrane 12 is transparent) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the transparent membrane teachings of Watson to the membrane disclosed by Smith in order to arrive at an invention which advantageously promotes needle-skin penetration by enabling an operator visualize the skin target throughout the insertion process. However, Smith is silent regarding: wherein the elastomeric, self-sealing membrane includes an antimicrobial agent. However, Smith teaches that the patch itself may be impregnated/applied with a medicated substance page 9 line 28-30 and page 15 line 26-29. Notably, MPEP 2144.04(VI)(B) provides that a modification of the prior art amounting to a mere duplication of parts has no patentable significance unless a new and unexpected result is produced. Accordingly, duplicating the medicated substance in the absorbent material of patch 1 of Smith such that there is a medicated substance in another part of patch 1 as well would similarly lack patentable significance as a new and unexpected result is not produced by such a modification. Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to duplicate the antimicrobial medicated substance of Smith such that it is incorporated in another portion of Smith, and consequently disposed in the claimed element, in order to advantageously arrive at an invention with improved capabilities to ward off microbial contamination. Claims 2-3 and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Smith or Smith in view of Watson, as applied to claim 1 and 14 above, in view of US 4781712 A, henceforth written as Barabino. Regarding Claim 2, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above, including the following limitations of the present claim: The puncture site patch of claim 1, wherein the at least one elongated tab is a first elongated tab wherein the first -- elongated tabs each extend outward from the periphery of the spacer (cover flap 5 and flap 14 extend away from zone 7 of patch 1; fig 1-4) However Smith is silent regarding: -- and the puncture site patch further includes a second elongated tab, wherein the first and second elongated tabs each extend outward from the periphery of the spacer and are disposed directly opposing each other. However, Barabino teaches a folded absorptive dermatological medical device: and [the invention] further includes a second elongated tab, wherein the first and second elongated tabs each extend outward from the periphery of the [center of the invention] and are disposed directly opposing each other. (col 4 line 57 to col 5 line 38; absorbent pad 10 can have its opposingly disposed elongate tabs panel 20 & liner 22 and wrapper panel 16 & wrapper panel 18, folded to overlap with eachother and provide an improved seal of the used inner contents of pad 10; fig 1-4) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the multiple opposing tab teachings of Barabino to the modified puncture site patch disclosed by Smith, such that Barabino’s second elongated tab is disposed opposite Smith’s elongated tab as well as subsequent elongate tabs of Barabino are disposed perpendicular to Smith’s elongated tab, in order to advantageously arrive at an invention with improved sealing means for protecting a user from contamination during the disposal of a used medical product, see col 4 line 57 to col 5 line 38 of Barabino. Regarding claim 3, Smith and Barabino teaches: The puncture site patch of claim 2, wherein in the second position the first and second elongated tabs substantially overlap each other. Examiner notes that in light of the modification of Smith and Barabino above, the incorporated multitude of elongated tabs overlap with one another so as to improve the sealing of the contaminated underside of Smith’s patch 1 when the modified invention is in the claimed second position. Regarding Claim 16, Smith in view of Watson discloses all of the elements of the current invention which the present claim is dependent upon, as described above, including the following limitations of the present claim: The puncture site patch of claim 14, wherein the at least one elongated tab is a first elongated tabwherein the first -- elongated tabs each extend outward from the periphery of the spacer (cover flap 5 and flap 14 extend away from zone 7 of patch 1; fig 1-4) However Smith is silent regarding: -- and the puncture site patch further includes a second elongated tab, wherein the first and second elongated tabs each extend outward from the periphery of the spacer and are disposed directly opposing each other. However, Barabino teaches a folded absorptive dermatological medical device: and [the invention] further includes a second elongated tab, wherein the first and second elongated tabs each extend outward from the periphery of the [center of the invention] and are disposed directly opposing each other. (col 4 line 57 to col 5 line 38; absorbent pad 10 can have its opposingly disposed elongate tabs panel 20 & liner 22 and wrapper panel 16 & wrapper panel 18, folded to overlap with eachother and provide an improved seal of the used inner contents of pad 10; fig 1-4) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the multiple opposing tab teachings of Barabino to the modified puncture site patch disclosed by Smith, such that Barabino’s second elongated tab is disposed opposite Smith’s elongate tab as well as subsequent elongate tabs of Barabino are disposed perpendicular to Smith’s elongated tab, in order to advantageously arrive at an invention with improved sealing means for protecting a user from contamination during the disposal of a used medical product, see col 4 line 57 to col 5 line 38 of Barabino. Claim 7 is rejected under 35 U.S.C. 103 as being unpatentable over Smith, as applied to claim 1 above, in view of US 20120082815 A1, henceforth written as Dehlinger. Regarding Claim 7, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above. However Smith is silent regarding: wherein the at least one elongated tab further included deadened adhesive. However, Dehlinger teaches a dressing patch: wherein the at least one elongated tab further included deadened adhesive. (paragraph 30; deadened adhesive is provided to promote removal of a protective release layer) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the deadened adhesive teachings of Dehlinger to the surface of the elongated tab disclosed by Smith in order to arrive at an invention which advantageously promotes removal of the protective release layer, see paragraph 30 of Dehlinger. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Smith, as applied to claim 9 above, in view of WO 2005049101 A1, henceforth written as Addison. Regarding Claim 12, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above. However Smith is silent regarding: wherein the antimicrobial agent is a plurality of silver nanoparticles. However, Addison teaches a dressing wherein the antimicrobial agent is a plurality of silver nanoparticles. ( page 1 line 16-19; it is well known to use silver nanoparticles as a form of antimicrobial compound) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to apply Addison's teachings of specific antimicrobial agents to the antimicrobial agent disclosed by Smith as it has art recognized suitability for the intended purpose of deterring microbes, see MPEP 2144.07. Claim 13 is rejected under 35 U.S.C. 103 as being unpatentable over Smith, as applied to claim 9 above, in view of US 20110034887 A1, henceforth written as Forden. Regarding Claim 13, Smith discloses all of the elements of the current invention which the present claim is dependent upon, as described above. However Smith is silent regarding: wherein the antimicrobial agent is a carvacrol agent incorporated into the elastomeric, self-sealing, membrane at a concentration of about 0.01% to about 0.001%. However, Forden teaches an antimicrobial agent wherein the antimicrobial agent is a carvacrol agent incorporated into the elastomeric, self-sealing, membrane at a concentration of about 0.01% to about 0.001%. (paragraph 78; any concentration of a blend of thymol and carvacrol is an effective antimicrobial agent, therein encompassing a concentration of “about 0.01% to about 0.001%”) Therefore, it would be obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention, to incorporate the specific antimicrobial agent teachings to the antimicrobial agent disclosed by Smith as it has art recognized suitability for the intended purpose of deterring microbes, see MPEP 2144.07. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FORREST DIPERT whose telephone number is (703)756-1704. The examiner can normally be reached M-F 8:30am-5pm eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached on (571) 270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /FORREST B DIPERT/Examiner, Art Unit 3783 /MICHAEL J TSAI/Supervisory Patent Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Show 2 earlier events
May 15, 2025
Response Filed
Jul 21, 2025
Final Rejection mailed — §103
Oct 07, 2025
Applicant Interview (Telephonic)
Oct 20, 2025
Request for Continued Examination
Oct 27, 2025
Response after Non-Final Action
Jun 25, 2026
Non-Final Rejection mailed — §103
Sep 25, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779134
PROTECTOR-ATTACHED PUNCTURE NEEDLE
4y 11m to grant Granted Nov 03, 2026
Patent 12741097
CONNECTION STRUCTURE AND LIQUID MEDICINE ADMINISTRATION TOOL
5y 0m to grant Granted Sep 22, 2026
Patent 12734299
FEEDBACK MECHANISMS
4y 4m to grant Granted Sep 15, 2026
Patent 12728239
Flexible Tubular Spring Structure, and Scoring Balloon Catheter Equipped Therewith
4y 10m to grant Granted Sep 08, 2026
Patent 12728212
SYSTEM AND METHOD FOR COLLECTING INJECTION INFORMATION
4y 0m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+64.4%)
3y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 54 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month